Therapies of mucopolysaccharidosis IVA (Morquio A syndrome)

Bibliography

• Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th edition. McGraw-Hill; New York: 2001. p. 3421-52
   Google Scholar
• Tomatsu S, Orii KO, Vogler C, et al. Mouse model for Galns-/- produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet 2003;12:3349-58
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Gutiérrez MA, Nishioka T, et al. Development of MPS IVA mouse (Galns tm(hC79mC76)slu) tolerant hGALNS. Hum Mol Genet 2005;14:3321-36
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Vogler C, Montaño AM, et al. Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins. Mol Genet Metab 2007;91:251-8
   PubMed Web of Science ®Google Scholar
• Montaño AM, Tomatsu S, Gottesman GS, et al. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis 2007;30:165-74
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Cur Pharm Biotech 2011;12:931-45
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Mackenzie WG, Theroux MC, et al. Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Res Rep Endocr Disord 2012;2:65-77
   Google Scholar
• Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis 2012;36:309-22
   PubMed Web of Science ®Google Scholar
• Takahashi-Nishioka T, Yokogawa K, Tomatsu S, et al. Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs. Curr Drug Discov Technol 2008;5:39-48
   PubMedGoogle Scholar
• De Franceschi L, Roseti L, Desando G, et al. A molecular and histological characterization of cartilage from patients with Morquio syndrome. Osteoarthritis Cartilage 2007;15:1311-17
   PubMed Web of Science ®Google Scholar
• Bank RA, Groener JE, van Gemund JJ, et al. Deficiency in N-acetylgalactosamine-6-sulfate sulfatase results in collagen perturbations in cartilage of Morquio syndrome A patients. Mol Genet Metab 2009;97:196-201
   PubMedGoogle Scholar
• Yasuda E, Fushimi K, Suzuki Y, et al. Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder. Mol Genet Metab 2013;109:301-11
   PubMed Web of Science ®Google Scholar
• Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8
   PubMed Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-73
   PubMed Web of Science ®Google Scholar
• Muenzer J, Lamsa JC, Garcia A, et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002;91:98-9
   PubMedGoogle Scholar
• Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004;144:574-80
   PubMed Web of Science ®Google Scholar
• Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005;115:e681-9
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-9
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008;94:469-75
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Frew E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type I. Health Technol Assess 2006;10(20):iii-v. ix-113
   Google Scholar
• Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007;67:2697-716
   PubMed Web of Science ®Google Scholar
• Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91
   PubMed Web of Science ®Google Scholar
• Parveen S, Sahoo SK. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 2006;45:965-88
   PubMed Web of Science ®Google Scholar
• Dickson P, Peinovich M, McEntee M, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 2008;118:2868-76
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Ohashi A, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 2008;17:815-24
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, DunG VC, et al. Enhancement of drug delivery: enzyme replacement therapy for murine Morquio A syndrome. Mol Ther 2012;18:1094-102
   Web of Science ®Google Scholar
• Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004;6:481-506
   PubMed Web of Science ®Google Scholar
• Hodges BL, Cheng SH. Cell and gene-based therapies for the lysosomal storage diseases. Curr Gene Ther 2006;6:227-41
   PubMed Web of Science ®Google Scholar
• Alméciga-Díaz CJ, Montaño AM, Tomatsu S, et al. Adeno-associated virus gene transfer in Morquio A disease: effect of promoters and sulfatase-modifying factor 1. FEBS J 2010;277:3608-19
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young E, Cooper A, et al. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999;22:638-48
   PubMed Web of Science ®Google Scholar
• Nishioka T, Tomatsu S, Gutierrez MA, et al. Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab 2006;88:244-55
   PubMed Web of Science ®Google Scholar
• Millán JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 2008;23:777-87
   PubMed Web of Science ®Google Scholar
• Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2011;8:904-13
   Google Scholar
• Kasugai S, Fujisawa R, Waki Y, et al. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res 2000;15:936-43
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Miya K, Sekido T, et al. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001;142:1228-33
   PubMed Web of Science ®Google Scholar
• Montaño A, Oikawa H, Tomatsu S, et al. Acidic amino acid tag enhances response to enzyme replacement in mucopolusaccharidosis type VII. Mol Genet Metab 2008;94:178-89
   PubMed Web of Science ®Google Scholar
• Theroux MC, Nerker T, Ditro C, et al. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth 2012;22:901-7
   PubMed Web of Science ®Google Scholar
• Takahashi T, Katsuta S, Tamura Y, et al. Bone-targeting endogenous secretory RAGE rescues rheumatoid arthritis. Mol Med 2013;19:183-94
   PubMedGoogle Scholar
• Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol 2010;33:589-604
   PubMed Web of Science ®Google Scholar
• Harmatz P. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures. Turk J Pediatr 2010;52:443-9
   PubMedGoogle Scholar
• Tylki-Szymanska A, Marucha J, Jurecka A, et al. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis 2010;33:151-7
   PubMedGoogle Scholar
• Crawley AC, Niedzielski KH, Isaac EL, et al. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Investig 1997;99:651-62
   PubMed Web of Science ®Google Scholar
• Simonaro CM, D'Angelo M, Haskins ME, et al. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005;57:701-7
   PubMed Web of Science ®Google Scholar
• Jespan J. Clinical trial of enzyme replacement therapy for Morquio A. The 2nd annual Morquio Conference; 19 – 21 July 2013; Wilmington, DE
   Google Scholar
• Dierks T, Schmidt B, Borissenko LV, et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C (alpha)-formylglycine generating enzyme. Cell 2003;113:435-44
   PubMed Web of Science ®Google Scholar
• Cosma MP, Pepe S, Annunziata I, et al. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 2003;113:445-56
   PubMed Web of Science ®Google Scholar
• Ohashi A, Montaño AM, Colón JE, et al. Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease. Acta Paediatr 2009;98:768-9
   PubMed Web of Science ®Google Scholar
• Beck M, Braun S, Coerdt W, et al. Fetal presentation of Morquio disease type A. Prenat Diagn 1992;12:1019-29
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Jurecka A, Zuber Z, et al. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: 3-year follow-up. Acta Paediatr 2012;101:e42-7
   PubMed Web of Science ®Google Scholar
• Rowan DJ, Tomatsu S, Grubb JH, et al. Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Mol Genet Metab 2012;107:161-72
   PubMed Web of Science ®Google Scholar
• Willyard C. Limb-saving medicines sought to prevent amputations. Nat Med 2012;18:328
   PubMedGoogle Scholar
• Gruber K. Europe gives gene therapy the green light. Lancet 2012;380:e10
   Google Scholar
• Seregin SS, Amalfitano A. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects. Curr Pharm Des 2011;17:2558-74
   PubMedGoogle Scholar
• Ponder K, Haskins M. Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 2007;7:1333-45
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/
   Google Scholar
• Osborn MJ, McElmurry RT, Peacock B, et al. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol Ther 2008;16:1459-66
   PubMed Web of Science ®Google Scholar
• Osborn MJ, McElmurry RT, Lees CJ, et al. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of alpha-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 2011;19:450-60
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Bell JB, Belur LR, et al. Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 2007;9:403-15
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Bell JB, Khan SA, et al. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 2009;17:1136-44
   PubMed Web of Science ®Google Scholar
• Baldo G, Wozniak DF, Ohlemiller KK, et al. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits. J Inherit Metab Dis 2013;36:499-512
   PubMed Web of Science ®Google Scholar
• Traas AM, Wang P, Ma X, et al. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol Ther 2007;15:1423-31
   PubMed Web of Science ®Google Scholar
• Herati RS, Knox VW, O'Donnell P, et al. Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol Genet Metab 2008;95:142-51
   PubMedGoogle Scholar
• Herati RS, Ma X, Tittiger M, et al. Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice. J Gene Med 2008;10:972-82
   PubMed Web of Science ®Google Scholar
• Metcalf JA, Ma X, Linders B, et al. A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Mol Ther 2010;18:334-42
   PubMed Web of Science ®Google Scholar
• Visigalli I, Delai S, Politi LS, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 2010;116:5130-9
   PubMed Web of Science ®Google Scholar
• Ellinwood NM, Ausseil J, Desmaris N, et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 2011;19:251-9
   PubMed Web of Science ®Google Scholar
• Wolf DA, Lenander AW, Nan Z, et al. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis 2011;43:123-33
   PubMed Web of Science ®Google Scholar
• Friso A, Tomanin R, Zanetti A, et al. Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS). Biochim Biophys Acta 2008;1782:574-80
   PubMedGoogle Scholar
• Jung SC, Park ES, Choi EN, et al. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy. Mol Cells 2010;30:13-18
   PubMed Web of Science ®Google Scholar
• Heldermon CD, Qin EY, Ohlemiller KK, et al. Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice. Gene Ther 2013; Epub ahead of print
   PubMedGoogle Scholar
• Fu H, Kang L, Jennings JS, et al. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 2007;14:1065-77
   PubMed Web of Science ®Google Scholar
• Fu H, Dirosario J, Killedar S, et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011;19:1025-33
   PubMed Web of Science ®Google Scholar
• Heldermon CD, Ohlemiller KK, Herzog ED, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther 2010;18:873-80
   PubMed Web of Science ®Google Scholar
• Ruzo A, Marco S, Garcia M, et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 2012;23:1237-46
   PubMed Web of Science ®Google Scholar
• Fu H, DiRosario J, Kang L, et al. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. J Gene Med 2010;12:624-33
   PubMed Web of Science ®Google Scholar
• Di DC, Villani GR, Di ND, et al. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A 2009;149A:1209-18
   PubMedGoogle Scholar
• McIntyre C, Byers S, Anson DS. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer. J Gene Med 2010;12:717-28
   PubMed Web of Science ®Google Scholar
• McIntyre C, Derrick RAL, Ranieri E, et al. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. Mol Genet Metab 2008;93:411-18
   PubMed Web of Science ®Google Scholar
• Lau AA, Hopwood JJ, Kremer EJ, et al. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Mol Genet Metab 2010;100:168-75
   PubMed Web of Science ®Google Scholar
• Lau AA, Rozaklis T, Ibanes S, et al. Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 2012;491:53-7
   PubMed Web of Science ®Google Scholar
• Cotugno G, Annunziata P, Tessitore A, et al. Long-term amelioration of feline mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther 2011;19:461-9
   PubMed Web of Science ®Google Scholar
• Ferla R, O'Malley T, Calcedo R, et al. Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. Hum Gene Ther 2013;24:163-9
   PubMed Web of Science ®Google Scholar
• Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199:381-90
   PubMed Web of Science ®Google Scholar
• Ponder KP, O'Malley TM, Wang P, et al. Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats. Mol Ther 2012;20:898-907
   PubMed Web of Science ®Google Scholar
• Byers S, Rothe M, Lalic J, et al. Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues. Mol Genet Metab 2009;97:102-8
   PubMedGoogle Scholar
• Richard M, Arfi A, Seguin J, et al. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Ther 2009;16:746-56
   PubMed Web of Science ®Google Scholar
• Smith LJ, Martin JT, O'Donnell P, et al. Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs. Mol Genet Metab 2012;107:145-52
   PubMed Web of Science ®Google Scholar
• Xing EM, Knox VW, O'Donnell PA, et al. The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade. Mol Genet Metab 2013;109:183-93
   PubMed Web of Science ®Google Scholar
• Macsai CE, Derrick-Roberts AL, Ding X, et al. Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII. Mol Genet Metab 2012;106:202-13
   PubMed Web of Science ®Google Scholar
• Chen YH, Claflin K, Geoghegan JC, et al. Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther 2012;20:1393-9
   PubMed Web of Science ®Google Scholar
• Husain T, Passini MA, Parente MK, et al. Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters. Gene Ther 2009;16:927-32
   PubMedGoogle Scholar
• Bielicki J, McIntyre C, Anson DS. Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII. Mol Genet Metab 2010;101:370-82
   PubMed Web of Science ®Google Scholar
• Toietta G, Severini G, Traversari C, et al. Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro. Hum Gene Ther 2001;12:2007-16
   PubMed Web of Science ®Google Scholar
• Alméciga-Díaz C, Montaño AM, Tomatsu S, et al. Adeno-associated virus gene transfer on Morquio A: effect of promoters and sulfatase-modifying factor 1. FEBS J 2010;277:3608-19
   PubMed Web of Science ®Google Scholar
• Alméciga-Díaz C, Rueda-Paramo M, Espejo A, et al. Effect of elongation factor 1α promoter and SUMF1 over in-vitro expression of N-acetylgalactosamine-6-sulfate sulfatase. Mol Biol Rep 2009;36:1863-70
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Garcia-Vallejo F, Tomatsu S, et al. Construction of an adenoassociated virus-derived vector for the treatment of Morquio A disease. Biomedica 2008;28:448-59
   PubMed Web of Science ®Google Scholar
• Papadakis E, Nicklin S, Baker A, et al. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther 2004;4:89-113
   PubMed Web of Science ®Google Scholar
• Alméciga-Díaz C, Montaño A, Tomatsu S, et al. Adeno-associated virus mediated gene therapy in a murine model of Morquio syndrome type A. Mol Genet Metab 2009;96:S13
   PubMedGoogle Scholar
• Buning H, Ried MU, Perabo L, et al. Receptor targeting of adeno-associated virus vectors. Gene Ther 2003;10:1142-51
   PubMed Web of Science ®Google Scholar
• Loiler SA, Conlon TJ, Song S, et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 2003;10:1551-8
   PubMed Web of Science ®Google Scholar
• Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 2005;5:299-310
   PubMed Web of Science ®Google Scholar
• White K, Buning H, Kritz A, et al. Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther 2008;15:443-51
   PubMedGoogle Scholar
• Alméciga-Díaz C, Cuaspa R, Barrera L. Gene delivery systems: tailoring vectors to reach specific tissues. In: Yuan X, editor. Non-viral gene therapy. InTech; Rijeka, Croatia: 2011. p. 51-76
   Google Scholar
• Alméciga-Díaz C, Montaño A, Tomatsu S, et al. Contribución colombiana al conocimiento de la enfermedad de Morquio. Medicina (Mex) 2012;34:221-41
   Google Scholar
• Tomatsu S, Montaño AM, Alméciga-Díaz C, et al. Delivery of therapeutic agents to the bone. US20100008979; 2010
   Google Scholar
• Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Cur Pharm Biotech 2012;12(6):931-45
   Google Scholar
• Tomatsu S, Mackenzie WG, Theroux MC, et al. Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Res Rep Endocr Dis 2012;2:65-77
   Google Scholar
• Alméciga-Díaz C, Herrera J, Barbosa H, et al. New viral vectors for Morquio syndrome type A gene therapy. Mol Genet Metab 2013;108:S19
   Google Scholar
• Ma X, Liu Y, Tittiger M, et al. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 2007;15:889-902
   PubMed Web of Science ®Google Scholar